

APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

Purchase of own shares - 9th Interim notification

Monheim am Rhein, 22 August 2022. In the period from 15 August 2022 up to and including 19 August 2022, a total of 6,567 shares were purchased under the Share Buyback Program 2022/II. The launch and the details of the Share Buyback Program 2022/II were published by way of an announcement dated 23 June 2022 pursuant to Article 5 paragraph 1 of Regulation (EU) No. 596/2014 and Article 2 paragraph 1 of the Delegated Regulation (EU) No. 2016/1052.

The total number of shares purchased in the period from 15 August 2022 up to and including 19 August 2022 per day, exchange, average price and volume in euros are as follows:

Date	Total number of shares purchased (number)	Average price (Euro)	Exchange	Volume (Euro) ¹
15/08/2022	1,178	11.2544	Xetra	13,257.65
16/08/2022	1,227	10.8630	Xetra	13,328.90
17/08/2022	1,524	11.0740	Xetra	16,876.85
18/08/2022	1,151	11.0181	Xetra	12,681.80
19/08/2022	1,487	11.2274	Xetra	16,695.10

1) Excluding acquisition costs

The total number of shares purchased to date as part of the Share Buyback Program 2022/II up to and including 19 August 2022 amounts to 55,070 shares.

The share buyback was carried out by Hauck Aufhäuser Lampe Privatbank AG.



Further details on the Share Buyback Program 2022 and the above transactions are published under the Corporate Governance section of the Company's Investor Relations website in accordance with Article 5 of Regulation (EU) No. 596/2014 and pursuant to Delegated Regulation (EU) No. 2016/1052 (<https://ir.apontis-pharma.de/websites/apontispharma/English/4000/corporate-governance.html>).

APONTIS PHARMA AG

Investor Relations

ir@apontis-pharma.de

T: +49 2173 89 55 4900

F: +49 2173 89 55 1521

Alfred-Nobel-Str. 10

40789 Monheim am Rhein

Germany

apontis-pharma.de

APONTIS PHARMA Presse Contact

CROSS ALLIANCE communication GmbH

Sven Pauly

ir@apontis-pharma.de

T: +49 89 125 09 0330